BACKGROUND: Itraconazole is the preferred azole for histoplasmosis in the current Infectious Diseases Society of America guidelines. Voriconazole is increasingly used as treatment for histoplasmosis; it has in vitro activity against Histoplasma capsulatum and has shown success in case reports and small case series, but may have a lower barrier to resistance. No comparative studies have been published. METHODS: We constructed a single-center, retrospective cohort of adult patients diagnosed with histoplasmosis from 2002 to 2017. Individual charts were reviewed to gather clinical information, including demographics, clinical features, immune status, treatments, and mortality. Patients were categorized based on the choice of azole and use as an initial treatment or as a step-down therapy from amphotericin B. Initial therapies with other azoles were excluded. Mortality was compared using a multivariable Cox proportional hazards with Heaviside function at 42 days. RESULTS: We identified 261 cases of histoplasmosis from 2002 to 2017. After excluding patients not treated with itraconazole or voriconazole, 194 patients remained. Of these, 175 (90%) patients received itraconazole and 19 (10%) received voriconazole. There were no significant demographic differences between patient populations receiving either azole as their initial azole treatment. Death at 180 days occurred in 41 patients (23.4%) in the itraconazole group and 6 patients (31.6%) in the voriconazole group. Patients on voriconazole had a statistically significant increase in mortality during the first 42 days after initiation of treatment when compared to patients receiving itraconazole (hazard ratio, 4.30; 95% confidence interval, 1.3-13.9; P = .015), when controlled for other risk factors. CONCLUSIONS: Voriconazole in histoplasmosis was associated with increased mortality in the first 42 days when compared to itraconazole.
BACKGROUND: Itraconazole is the preferred azole for histoplasmosis in the current Infectious Diseases Society of America guidelines. Voriconazole is increasingly used as treatment for histoplasmosis; it has in vitro activity against Histoplasma capsulatum and has shown success in case reports and small case series, but may have a lower barrier to resistance. No comparative studies have been published. METHODS: We constructed a single-center, retrospective cohort of adult patients diagnosed with histoplasmosis from 2002 to 2017. Individual charts were reviewed to gather clinical information, including demographics, clinical features, immune status, treatments, and mortality. Patients were categorized based on the choice of azole and use as an initial treatment or as a step-down therapy from amphotericin B. Initial therapies with other azoles were excluded. Mortality was compared using a multivariable Cox proportional hazards with Heaviside function at 42 days. RESULTS: We identified 261 cases of histoplasmosis from 2002 to 2017. After excluding patients not treated with itraconazole or voriconazole, 194 patients remained. Of these, 175 (90%) patients received itraconazole and 19 (10%) received voriconazole. There were no significant demographic differences between patient populations receiving either azole as their initial azole treatment. Death at 180 days occurred in 41 patients (23.4%) in the itraconazole group and 6 patients (31.6%) in the voriconazole group. Patients on voriconazole had a statistically significant increase in mortality during the first 42 days after initiation of treatment when compared to patients receiving itraconazole (hazard ratio, 4.30; 95% confidence interval, 1.3-13.9; P = .015), when controlled for other risk factors. CONCLUSIONS: Voriconazole in histoplasmosis was associated with increased mortality in the first 42 days when compared to itraconazole.
Authors: L Joseph Wheat; Patricia Connolly; Nicholas Haddad; Ann Le Monte; Edward Brizendine; Richard Hafner Journal: Antimicrob Agents Chemother Date: 2002-01 Impact factor: 5.191
Authors: Lawrence J Wheat; Marwan M Azar; Nathan C Bahr; Andrej Spec; Ryan F Relich; Chadi Hage Journal: Infect Dis Clin North Am Date: 2016-03 Impact factor: 5.982
Authors: Gloria M González; Annette W Fothergill; Deanna A Sutton; Michael G Rinaldi; David Loebenberg Journal: Med Mycol Date: 2005-05 Impact factor: 4.076
Authors: David I Marks; Antonio Pagliuca; Christopher C Kibbler; Axel Glasmacher; Claus-Peter Heussel; Michal Kantecki; Paul J S Miller; Patricia Ribaud; Haran T Schlamm; Carlos Solano; Gordon Cook Journal: Br J Haematol Date: 2011-08-22 Impact factor: 6.998
Authors: Patrick B Mazi; Sandra R Arnold; John W Baddley; Nathan C Bahr; Susan E Beekmann; Todd P McCarty; Philip M Polgreen; Adriana M Rauseo; Andrej Spec Journal: Open Forum Infect Dis Date: 2022-06-24 Impact factor: 4.423
Authors: George R Thompson; Thuy Le; Ariya Chindamporn; Carol A Kauffman; Ana Alastruey-Izquierdo; Neil M Ampel; David R Andes; Darius Armstrong-James; Olusola Ayanlowo; John W Baddley; Bridget M Barker; Leila Lopes Bezerra; Maria J Buitrago; Leili Chamani-Tabriz; Jasper F W Chan; Methee Chayakulkeeree; Oliver A Cornely; Cao Cunwei; Jean-Pierre Gangneux; Nelesh P Govender; Ferry Hagen; Mohammad T Hedayati; Tobias M Hohl; Grégory Jouvion; Chris Kenyon; Christopher C Kibbler; Nikolai Klimko; David C M Kong; Robert Krause; Low Lee Lee; Graeme Meintjes; Marisa H Miceli; Peter-Michael Rath; Andrej Spec; Flavio Queiroz-Telles; Ebrahim Variava; Paul E Verweij; Ilan S Schwartz; Alessandro C Pasqualotto Journal: Lancet Infect Dis Date: 2021-08-06 Impact factor: 71.421